MedTrace Logo

Efficacy and Safety of Flutiform® pMDI in Adult Patients With Mild to Moderate-severe Reversible Asthma

NCT00476073 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 228

Last updated 2018-10-24

No results posted yet for this study

Summary

Open, parallel group design. The study has a screening phase and a 12 week treatment phase. Subjects will be randomised to treatment in a 1:1 ration.

Conditions

  • Asthma Bronchiale

Interventions

DRUG

FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)

Sponsors & Collaborators

  • Mundipharma Research Limited

    lead INDUSTRY

Principal Investigators

  • Dr Blagden, MD

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00476073 on ClinicalTrials.gov